electroCore, Inc. (ECOR) News
Filter ECOR News Items
ECOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ECOR News Highlights
- ECOR's 30 day story count now stands at 2.
- Over the past 3 days, the trend for ECOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ECOR are BEN, STIM and TAC.
Latest ECOR News From Around the Web
Below are the latest news stories about ELECTROCORE INC that investors may wish to consider to help them evaluate ECOR as an investment opportunity.
electroCore, Inc. Announces Departure of JP Errico from the Board of DirectorsROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr. Errico will continue as a consultant and strategic advisor to the Company, focused on supporting the growth and direction of the wellness and human performance brands, Truvaga™ and TAC-STIM™. “We are fortunate that electroCore will continue to ben |
electroCore to Participate at 13th Annual LD Micro Invitational XIIIROCKAWAY, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023. LD Micro Invitational XIII:Date: Tuesday, June 6, 2023 Time: 11:00 AM PTEvent: PresentationVirtual viewers: Livestream For more information regarding the |
ECOR: Getting A BOOST from New InitiativesBy John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT First Quarter 2023 Financial and Operational Results For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented |
electroCore Announces First Quarter 2023 Financial ResultsRecord first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2023 financial results and provided an operational update. First Quarter 2023 and Recent Highlights Record revenue of $2.8 million, an incr |
electroCore to Participate at Annual Aegis Virtual ConferenceROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023. Aegis Capital Conference:Date: Tuesday, May 2, 2023 Time: 4:00 PM ETEvent: Presentation here About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and |
National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use DisordersROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Emory University and the Georgia Institute of Technology a 3-year, $6.0 million grant through the NIH Helping to End Addiction Long Term (HEAL) Initiative to conduct a pivotal clinical trial of gammaCore (non-invasive vagus |
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language LearningClinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participantsROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research Laboratories (AFRL) reported data from its study on the ability of gammaCore non-inva |
electroCore to Announce First Quarter Financial Results on Wednesday, May 3ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 3, 2023, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conf |
electroCore Provides Select First Quarter 2023 Financial GuidanceRecord revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46% increase over first quarter of 2022 Revenue in first full quarter of Truvaga sales of approximately $147,000 expected ROCKAWAY, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first quarter of 2023. Financial GuidancePreliminary |
electroCore Expands Intellectual Patent Portfolio for nVNS TechnologyelectroCore Granted Three New U.S. PatentsROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The three patents were issued on April 11, 2023, and relate to the electroCore’s non-invasive vagus nerve stimulation (nVNS) technology, including the following patents: US Patent Nos. |